Disease · MONDO_0004648
Targets76
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 76
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ACHE | Acetylcholinesterase | 4 | Acetylcholinesterase inhibitor; Cholinesterases; ACHE & BCHE inhibitor | Phase 3 | https://conductscience.org/library/genes/43 | Drugs and targets |
| ADRA1A | Adrenergic receptor alpha | 1 | Adrenergic receptor alpha antagonist | Phase 2 | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor alpha | 1 | Adrenergic receptor alpha antagonist | Phase 2 | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor alpha | 1 | Adrenergic receptor alpha antagonist | Phase 2 | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRA2A | Adrenergic receptor alpha | 1 | Adrenergic receptor alpha antagonist | Phase 2 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha | 1 | Adrenergic receptor alpha antagonist | Phase 2 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor alpha | 1 | Adrenergic receptor alpha antagonist | Phase 2 | https://conductscience.org/library/genes/152 | Drugs and targets |
| BCHE | Cholinesterases; ACHE & BCHE | 1 | Cholinesterases; ACHE & BCHE inhibitor | Phase 3 | https://conductscience.org/library/genes/590 | Drugs and targets |
| CCR5 | C-C chemokine receptor type 5 | 1 | C-C chemokine receptor type 5 antagonist | Phase 2 | https://conductscience.org/library/genes/1234 | Drugs and targets |
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Early phase 1 | https://conductscience.org/library/genes/4697 | Drugs and targets |
| COXFA4L2 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Early phase 1 | https://conductscience.org/library/genes/56901 | Drugs and targets |
| DRD1 | Dopamine receptor | 1 | Dopamine receptor agonist | Phase 2 | https://conductscience.org/library/genes/1812 | Drugs and targets |
| DRD2 | Dopamine receptor | 1 | Dopamine receptor agonist | Phase 2 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| DRD3 | Dopamine receptor | 1 | Dopamine receptor agonist | Phase 2 | https://conductscience.org/library/genes/1814 | Drugs and targets |
| DRD4 | Dopamine receptor | 1 | Dopamine receptor agonist | Phase 2 | https://conductscience.org/library/genes/1815 | Drugs and targets |
| DRD5 | Dopamine receptor | 1 | Dopamine receptor agonist | Phase 2 | https://conductscience.org/library/genes/1816 | Drugs and targets |
| GABRA1 | GABA A receptor alpha-1/beta-1/gamma-2 | 1 | GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator | Unknown | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRB1 | GABA A receptor alpha-1/beta-1/gamma-2 | 1 | GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator | Unknown | https://conductscience.org/library/genes/2560 | Drugs and targets |
| GABRG2 | GABA A receptor alpha-1/beta-1/gamma-2 | 1 | GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator | Unknown | https://conductscience.org/library/genes/2566 | Drugs and targets |
| GPD2 | Glycerol-3-phosphate dehydrogenase, mitochondrial | 1 | Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor | Early phase 1 | https://conductscience.org/library/genes/2820 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004648/targets